Catalyst Pharmaceuticals reports Q3 non-GAAP EPS 57c, consensus 30c

Reports Q3 revenue $128.7M, consensus $123.42M. “Our strong financial performance reflects our unwavering commitment to operational and commercial excellence, driving sustained momentum and long-term growth. The early success of our newest product, AGAMREE, along with the continued robust organic growth of our flagship product, FIRDAPSE(R), highlights the strength of our U.S. commercial strategy, with revenues exceeding expectations and significantly contributing to our overall success,” stated Richard J. Daly, President and CEO of Catalyst. “Through our strategic partnerships, we are advancing initiatives to expand the geographic footprint of our rare disease portfolio in key territories outside the U.S. As we pursue opportunities aligned with our long-term growth objectives and forge new partnerships to broaden our global presence, our achievements to date underscore the strength of our strategic vision to address critical unmet medical needs, driven by the outstanding execution of our teams. With a resolute focus on sustained growth and value creation, we are optimistic about the path ahead and remain confident in meeting our full-year 2024 revenue guidance, laying a strong foundation for continued success.”